Sarepta Therapeutics said early Tuesday that a patient had died after receiving its gene therapy Elevidys, which treats the ...

A few weeks after Sarepta Therapeutics confirmed a patient died after receiving its drug Elevidys, research published April 3 ...

A patient has died while receiving Elevidys, a gene therapy for Duchenne muscular dystrophy, marking the first known death linked to the treatment. The company behind the drug, Sarepta ...

Sarepta Therapeutics said on Tuesday that a 16-year-old boy died from acute liver failure months after receiving the company's U.S-approved gene therapy for a rare muscular dystrophy. The patient ...

WASHINGTON (AP) — Sarepta Therapeutics said Tuesday that a patient died while taking its closely watched gene therapy for muscular ... from an Alabama woman after a record 130 days The House ...

The patient, a young man, suffered acute liver failure after receiving the therapy ... death. Fatalities have also been reported following the launch of Novartis’s Zolgensma, an AAV-delivered ...

Sarepta Therapeutics said Tuesday that a 16-year-old boy died after receiving Elevidys, its gene therapy ... noted that over 800 patients have now been treated with the therapy.

Sarepta reported a patient death from acute liver failure after Elevidys treatment ... moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne muscular dystrophy.